Related Experiment Videos
Calcitonin for prevention of postmenopausal bone loss
I MacIntyre1, J C Stevenson, M I Whitehead
1Endocrine Unit, Royal Postgraduate Medical School, London.
Lancet (London, England)
|April 23, 1988
Abstract:
A 2-year randomised pilot study was conducted in 70 patients to see whether the osteoclast-inhibiting effect of calcitonin would reduce postmenopausal vertebral bone loss. An oestradiol-treated group was included in the study as a positive control since oestrogens are known to be effective. Calcitonin reduced vertebral bone loss in doses above 250 micrograms human calcitonin (50 international units) a week, and at this dose was as effective as oestradiol.